China Resources Double-Crane Pharmaceutical Co.,Ltd. acquired 50.1% stake in Shenzhou Biology & Technology Co., Ltd from Aerospace Shenzhou Biology & Technology Group Co., Ltd , China Aerospace Investment Holdings Ltd , China Spacesat Co.,Ltd. and Beijing Dawn Aerospace Bio-tech Co., Ltd.
August 30, 2022
Share
China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd from Aerospace Shenzhou Biology & Technology Group Co., Ltd , China Aerospace Investment Holdings Ltd , China Spacesat Co.,Ltd. (SHSE:600118) and Beijing Dawn Aerospace Bio-tech Co., Ltd. for approximately CNY 500 million on August 1, 2022.Aerospace Shenzhou Biology & Technology Co., Ltd holds 21.88% of Shenzhou Biology & Technology Co., Ltd., 16.33% of Shenzhou Biology & Technology Co., Ltd. held by Aerospace Investment Holdings Co., Ltd, 8.33% of Shenzhou Biology & Technology Co., Ltd. by China Spacesat Co.,Ltd., and 3.57% of Shenzhou Biology & Technology Co., Ltd. by Beijing Dawn Aerospace Bio-tech Co., Ltd. This has been approved in the 18th Meeting of the Company's 9th Directorate held on July 15, 2022.
China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) completed the acquisition of 50.1% stake in Shenzhou Biology & Technology Co., Ltd from Aerospace Shenzhou Biology & Technology Group Co., Ltd , China Aerospace Investment Holdings Ltd , China Spacesat Co.,Ltd. (SHSE:600118) and Beijing Dawn Aerospace Bio-tech Co., Ltd. on August 31, 2022.
China Spacesat Co Ltd is a China-based company principally engaged in aerospace manufacturing and satellite applications. The aerospace manufacturing business mainly includes satellite system development and aerospace component manufacturing. The satellite application business mainly includes satellite application technology equipment manufacturing and satellite application services. The Company mainly operates its businesses in China, with North, Northwest and South China as its main market.
CHINA SPACESAT CO.,LTD. 
